Ascensia partnership puts the London healthtech’s microsensor on the road to a European launch – with ambitions that run well ...

MUST’s RETRO-EPIGERNA team won $1 million and a place in the $81 million finals, though key trial details remain undisclosed.

A new partnership is combining a blood test, a cognitive app and national infrastructure to cut Britain’s years-long ...

Neither the FDA nor EMA recognizes aging as an indication – but the drafts, the precedent and the people on record are ...

Oxford biotech secures $47 million to scale cell-based mRNA manufacturing, with an eye on therapies that require repeated ...

Deep Longevity’s new US telehealth platform, Accrua, ties treatment plans to a blood-based aging score and re-tests every ...

The Parkinson’s enzyme therapy is still heading toward the clinic, and the deal could grow by up to $1.17bn in milestone ...

The Austin-based microbiome testing company raised a $33M Series B, and adults now outnumber babies in its testing volume.

Swedish biotech will present the Phase II ADVANCE trial design for vaccine candidate ALZ-101 at Alzheimer’s disease ...

First-in-human ER-100 data support dose escalation, with early visual-field signals in two of three glaucoma patients.

Novartis’ President of Biomedical Research, Fiona Marshall, on what it would take for big pharma to go all in on longevity. When the person who runs research for one of the world’s largest drug ...